Compare Amanta Healthcar with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
INR 401 Cr (Micro Cap)
39.00
33
0.00%
0.40
4.98%
1.94
Total Returns (Price + Dividend) 
Amanta Healthcar for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Amanta Healthcar is Rated Sell
Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Amanta Healthcar is Rated Sell by MarketsMOJO
Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Amanta Healthcare Evaluation Sees Shift Amidst Mixed Financial Signals
Amanta Healthcare’s recent market assessment reflects a nuanced picture shaped by its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s long-term sales trajectory, debt servicing capacity, and return ratios have influenced a revision in its evaluation, highlighting both challenges and areas of relative strength within a competitive sector.
Read full news article Announcements 
Appointment Of Investor Relation (IR) Agency
10-Jan-2026 | Source : BSEAppointment of Investor Relation (IR) Agency
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
07-Jan-2026 | Source : BSEcertificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Announcement Under Regulation 30
02-Jan-2026 | Source : BSEAnnouncement under Regulation 30
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (2.46%)
Held by 9 FIIs (2.21%)
Bhavesh Girishbhai Patel (16.1%)
Bandhan Small Cap Fund (2.46%)
20.28%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 8.54% vs -9.37% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -65.53% vs -41.11% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Nine Monthly Results Snapshot (Standalone) - Mar'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Standalone) - Mar'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period






